PFE: Company disclosure

Item 7.01 Regulation FD Disclosure Following the disclosure of Pfizer’s Chief Financial Officer transition announcement on June 18, 2026, Pfizer today is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first quarter earnings call on May 5, 2026. The company is reaffirming all components of its full-year 2026 guidance previously announced, including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00. Additional information, including defined terms, can be found in Pfizer’s 2026 First Quarter Earnings Release, issued on May 5, 2026.Following the disclosure of Pfizer’s Chief Financial Officer transition announcement on June 18, 2026, Pfizer today is reaffirming its fiscal year 2026 guidance introduced December 16, 2025 and reaffirmed on its first quarter earnings call on May 5, 2026. The company is reaffirming all components of its full-year 2026 guidance previously announced, including Revenues in a range of $59.5 to $62.5 billion and Adjusted Diluted EPS in a Range of $2.80 to $3.00. Additional information, including defined terms, can be found in Pfizer’s 2026 First Quarter Earnings Release, issued on May 5, 2026. DISCLOSURE NOTICE: Except where otherwise noted, the information contained in this Current Report on Form 8-K is as of June 18, 2026. We assume no obligation to update any forward-looking statements contained in this Form 8-K as a result of new information or future events or developments. This Current Report on Form 8-K contains forward-looking statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections. Given their forward-looking nature, these statements involve substantial risks, uncertain